Immix Biopharma
relapsed refractory multiple myeloma key inclusion criteria immix | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
March 2024
Slide
38 of 56
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
January 2024
relapsed refractory multiple myeloma key inclusion criteria | Immix Biopharma
Investor Presentation
December 2023
relapsed refractory multiple myeloma key inclusion criteria | Immix Biopharma
Investor Presentation
November 2023
relapsed refractory multiple myeloma key inclusion criteria | Immix Biopharma
Investor Presentation
November 2023
relapsed refractory multiple myeloma key inclusion criteria | Immix Biopharma
Related slides by other companies
Alkermes
Investor Presentation
October 2023
artistry phase potentially registrational study for mucosal melanoma | Alkermes
Bionomics
Investor Presentation
April 2022
phase attune study underway phase fast track designation from topline data expected be week placebo key inclusion criteria | Bionomics
Alkermes
Investor Presentation
October 2023
artistry phase potentially registrational study for platinum resistant ovarian cancer | Alkermes
Legend Biotech
Investor Presentation
April 2025
multiple myeloma | Legend Biotech
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights